Related references
Note: Only part of the references are listed.Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Simultaneous Multiplexed Imaging of mRNA and Proteins with Subcellular Resolution in Breast Cancer Tissue Samples by Mass Cytometry
Daniel Schulz et al.
CELL SYSTEMS (2018)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients
Bojiang Chen et al.
PLOS ONE (2017)
Precision medicine for metastatic breast cancer-limitations and solutions
Monica Arnedos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics
Chia-Feng Tsai et al.
NATURE COMMUNICATIONS (2015)
Application of molecular technologies for phosphoproteomic analysis of clinical samples
M. Pierobon et al.
ONCOGENE (2015)
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer
Gayle S. Jameson et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients
Karin Beelen et al.
BREAST CANCER RESEARCH (2014)
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
Karin Beelen et al.
BREAST CANCER RESEARCH (2014)
Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
Josefine Bostner et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials
Elin Karlsson et al.
BREAST CANCER RESEARCH (2013)
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
Julia D. Wulfkuhle et al.
CLINICAL CANCER RESEARCH (2012)
Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Fen Wang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
M. Caraglia et al.
CELL DEATH & DISEASE (2011)
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Ivette F. Emery et al.
BMC CANCER (2009)
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates
Nikesh Kotecha et al.
CANCER CELL (2008)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
